A Phase I Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Selected Relapsed / Refractory GPNMB-Expressing Solid Tumors
Dr. Doug Mahoney, University of Calgary
Approved October 2024 | Project Value $6,225,194 | Partners 6 | $997,463 from BioCanRx
Approved October 2024 | Project Value $6,225,194 | Partners 6 | $997,463 from BioCanRx
Eligible cancers: Solid tumors
Keywords CAR T cell Therapy, GPNMB, Immunotherapy, Alveolar soft part sarcoma, Renal cell carcinoma, Triple-negative breast cancer, Phase I clinical trial
An Interventional, Open-label, Non-randomized Dose-escalation Phase I Multicenter Clinical Trial of Multi-peptide Anti-minor Histocompatibility Antigen Immunotherapy for the Prevention of Relapse in Patients with High-risk Malignancy Eligible for Matched Related ASCT
Dr. Denis Claude Roy, HMR
Approved July 1, 2020 | Project value $ 1,600,000 | 3 partners | $675,000 from BioCanRx
Approved July 1, 2020 | Project value $ 1,600,000 | 3 partners | $675,000 from BioCanRx
Eligible cancers: Hematologic
Phase II CYTOSHRINK Trial: Cytoreductive Stereotactic Hypofractionated Radiotherapy with Combination Ipilimumab and Nivolumab for Metastatic Kidney Cancer
Dr. Aly-Khan A. Lalani, McMaster University
Approved April 1, 2020 | Project value $ 1,320,000 | 2 partners | $489,870 from BioCanRx
Approved April 1, 2020 | Project value $ 1,320,000 | 2 partners | $489,870 from BioCanRx
Eligible cancers: Metastatic Kidney
The Selected Tumor-infiltrating Lymphocyte Against Refractory Melanoma-01 Trial (STAR-M01)
Dr. Simon Turcotte, CHUM
Approved October 1, 2020 | Project value $ 2,980,000 | 9 partners | $675,000 from BioCanRx
Approved October 1, 2020 | Project value $ 2,980,000 | 9 partners | $675,000 from BioCanRx
Eligible cancers: Metastatic Melanoma
COV-IMMUNO- A randomized phase III trial of immunization with IMM-101 versus observation for the prevention of serious respiratory and COVID-19 related infections in cancer patients at increased risk of exposure
Dr. Rebecca Auer, Ottawa Hospital Research Institute
Approved April 1, 2020 | Project value $ 2,790,000 | 7 partners | $750,000 from BioCanRx
Approved April 1, 2020 | Project value $ 2,790,000 | 7 partners | $750,000 from BioCanRx
Eligible cancers: Solid Tumours, Myeloma, and Lymphoma
Keywords: COVID-19, IMM-101, vaccine, trained immunity
Keywords: COVID-19, IMM-101, vaccine, trained immunity
Canadian-Led Immunotherapies in Cancer: CLIC-1901 for the Treatment of Patients with Relapsed/Refractory CD19 Positive Hematologic Malignancies
Dr. Natasha Kekre, Ottawa Hospital Research Institute
Approved May 15, 2019 | Project value $ 2,229,077 | 3 partners | $400,000 from BioCanRx
Approved May 15, 2019 | Project value $ 2,229,077 | 3 partners | $400,000 from BioCanRx
Eligible cancers: Leukemia and Lymphoma
Keywords: CAR-T cells
Keywords: CAR-T cells
Phase Ib trial of pembrolizumab administered following adoptive cell therapy- A multiple cohort study; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
Dr. Marcus Butler, Princess Margaret Cancer Centre
Approved April 23, 2018 | Project value $ 2,430,424 | 2 partners | $500,000 from BioCanRx
Approved April 23, 2018 | Project value $ 2,430,424 | 2 partners | $500,000 from BioCanRx
Eligible cancers: Melanoma and ovarian cancer
Keywords: pembrolizumab, adoptive cell therapy, combination therapy, tumor infiltrating lymphocytes (TIL), IL-2
Keywords: pembrolizumab, adoptive cell therapy, combination therapy, tumor infiltrating lymphocytes (TIL), IL-2
Interrogation of Biomarkers in Patient Samples from a Phase Ib Trial of the Immune Checkpoint Inhibitor, Avelumab, in Combination with SMAC Mimetic Debio1143
Dr. Glenwood Goss, Ottawa Hospital Research Institute
Approved April 23, 2018 | Project value $19,867,177 | 4 partners | $779,777 from BioCanRx
Approved April 23, 2018 | Project value $19,867,177 | 4 partners | $779,777 from BioCanRx
Eligible cancers: Solid malignancies
Keywords: biomarkers, immune checkpoint inhibitor, Avelumab, Debio1143, combination therapy, SMAC mimetic
Keywords: biomarkers, immune checkpoint inhibitor, Avelumab, Debio1143, combination therapy, SMAC mimetic
PHASE I CLINICAL TRIAL OF ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN IMMUNOTHERAPY BROADENING THE SCOPE OF APPLICATION FOR PRECISION THERAPEUTICS
Drs Roy and Perreault, Hôpital Maisonneuve-Rosemont, Université de Montréal
Approved July 6, 2017 | Project value $2.6 M | 7 partners | $796,397 from BioCanRx
Approved July 6, 2017 | Project value $2.6 M | 7 partners | $796,397 from BioCanRx
Eligible cancers: hematologic cancers (specifically lymphoid HCs)
Keywords: T cells, Minor Histocompability Antigens (MiHAs), hematologic cancers, Graph-Versus-Tumour-Effect (GVTE)
Keywords: T cells, Minor Histocompability Antigens (MiHAs), hematologic cancers, Graph-Versus-Tumour-Effect (GVTE)
A Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 (MG1-E6E7), with Adenovirus Vaccine Expressing Mutant HPV E6 and E7 (Ad-E6E7) and Atezolizumab in Patients with HPV Associated Cancers
Drs Lichty, Ungerechts and Bell, McMaster University, The Ottawa Hospital Research Institute, University of Ottawa
Approved April 28, 2017 | Project value $5.3M | 2 partners | $780,665 from BioCanRx
Approved April 28, 2017 | Project value $5.3M | 2 partners | $780,665 from BioCanRx
Eligible cancers: human papilloma virus (specifically HPV-positive associated tumours)
Keywords: MG1, mutant human papilloma virus, E6, E7, MG1-E6E7, Adenovirus vaccine, Ad-E6E7, Ad/MG1-E6E7
Keywords: MG1, mutant human papilloma virus, E6, E7, MG1-E6E7, Adenovirus vaccine, Ad-E6E7, Ad/MG1-E6E7
CLINICAL TRIAL TO TEST THE ONCOLYTIC VACCINE APPROACH IN COMBINATION WITH CHECKPOINT INHIBITOR ANTIBODIES
Dr. Marcus Butler, Princess Margaret Cancer Centre, University Health Network
Approved June 10, 2015 | Project value $9 million | 2 partners | $750,000 from BioCanRx
Approved June 10, 2015 | Project value $9 million | 2 partners | $750,000 from BioCanRx
Eligible cancers: anal, bladder, breast, cervical, colon, esophageal, kidney, liver, lung, melanoma, mouth, ovarian, pancreatic, prostate, stomach, uterine
Keywords: oncolytic virus, oncolytic vaccine, antibody, immune checkpoint inhibitor, anti-PD-1 antibody, adenovirus vaccine, Maraba oncolytic virus, AdMA3, MG1MA3
Keywords: oncolytic virus, oncolytic vaccine, antibody, immune checkpoint inhibitor, anti-PD-1 antibody, adenovirus vaccine, Maraba oncolytic virus, AdMA3, MG1MA3
EVALUATING ADOPTIVE CELL THERAPY TO TREAT OVARIAN CANCER USING TILS CONDITIONED WITH DENDRITIC CELLS
Dr. Pamela Ohashi, Princess Margaret Cancer Centre, University Health Network
Approved June 10, 2015 | Project value $1.11 million | 1 partner | $434,381 from BioCanRx
Approved June 10, 2015 | Project value $1.11 million | 1 partner | $434,381 from BioCanRx
Eligible cancers: ovarian
Keywords: adoptive cell therapy, TIL cells, tumour-infiltrating lymphocytes, dendritic cells
Keywords: adoptive cell therapy, TIL cells, tumour-infiltrating lymphocytes, dendritic cells
PHASE I STUDY OF THERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML) USING AUTOLOGOUS AML CELLS ENGINEERED TO EXPRESS IL-12
Dr. Christopher Paige, University Health Network
Approved September 29, 2015 | Project value $1.34 million | 3 partners | $373,980 from BioCanRx
Approved September 29, 2015 | Project value $1.34 million | 3 partners | $373,980 from BioCanRx
Eligible cancers: Acute Myeloid Leukemia (AML)
Keywords: adoptive cell therapy, IL-12, Interleukin 12, autologous leukemia cells, AML
Keywords: adoptive cell therapy, IL-12, Interleukin 12, autologous leukemia cells, AML
